Pulmonary fibrosis has stolen a lot from me over the years. Like most people, I’d never heard of this cruel and life-threatening disease before my diagnosis of idiopathic pulmonary fibrosis (IPF) in 2016. I also had no idea how many other body systems are affected by chronic…
Body-shaming Comments Can Hurt People With Chronic Illness
Growing up in the Mexican culture, I was introduced to a lot of home remedies to treat everything — coughs, colds, stomachaches, fevers, bug bites, and even “el mal de ojo,” or the “evil eye.” Mexican folk medicine was an important part of my upbringing, but as an…
When I see an adult acting out in public, I find it annoying. If a front-line healthcare worker asks you to properly wear a mask in a clinical setting, please adjust your mask. Complaining about the rules and overreach of the U.S. Centers for Disease Control and Prevention (CDC)…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to EI-1071, an oral anti-inflammatory that Elixiron Immunotherapeutics is developing for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug status is awarded by the FDA to therapies designed to improve medical care for rare disorders —…
Algernon Pharmaceuticals’ experimental oral therapy NP-120 (ifenprodil) significantly reduced coughing in people with idiopathic pulmonary fibrosis (IPF), according to a new analysis of top-line data from a proof-of-concept Phase 2a clinical trial. The analysis showed the therapy was much more effective at easing cough than previously reported. NP-120’s “potential…
The day you’re diagnosed with a chronic illness is generally a day you won’t forget. The words from my doctor, Steven Nathan, made sense in the moment. They also became a collection of sound bites. They fall into three distinct categories: 1) you have, 2) you can expect, and…
A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases have been selected to receive a Horizon Therapeutics‘ #RAREis Global Advocate Grant. Winners of this year’s inaugural awards are spread across nine countries and represent a total of 29 rare…
A strong relationship with a medical specialist can make a world of difference. As a young adult living with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease, I have various specialists, but the one I value most is my pulmonologist. Before my diagnosis in 2016, I bounced…
Indulge me for one minute and think of some of the firsts you’ve experienced. What comes to mind? Is it the first time you tied your shoes? The first time you held your firstborn? The first time you drove a stick shift? If you flawlessly executed that last…
The U.S. Food and Drug Administration (FDA) has given fast-track designation to DWN12088, an experimental anti-fibrotic medication that Daewoong Pharmaceutical is developing to treat idiopathic pulmonary fibrosis (IPF). Fast track designation is given to therapies that are intended to treat serious conditions and fill an unmet medical need.
Your PF Community
Recent Posts
- New IPF therapy modulates genes tied to inflammation and scarring February 4, 2026
- My journey with PF and transplant means lifelong medical surveillance February 3, 2026
- Learning about the link between autoimmune disease and PF January 29, 2026
- Researchers ID 4 gene biomarkers that could help in early IPF diagnosis January 28, 2026
- How the PFF’s 5-year plan seeks to expand access to expert care January 27, 2026
